Supernus Pharmaceuticals (NASDAQ:SUPN) & Vectura Group (OTCMKTS:VEGPF) Financial Contrast

Vectura Group (OTCMKTS:VEGPF) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Volatility & Risk

Vectura Group has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.

Profitability

This table compares Vectura Group and Supernus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vectura Group	N/A	N/A	N/A
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%

Earnings & Valuation

This table compares Vectura Group and Supernus Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vectura Group	$244.76 million	4.37	$157.16 million	$0.26	6.81
Supernus Pharmaceuticals	$718.95 million	3.84	-$38.55 million	($1.92)	-24.71

Vectura Group has higher earnings, but lower revenue than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Vectura Group, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Vectura Group and Supernus Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vectura Group	0	0	0	0	0.00
Supernus Pharmaceuticals	1	1	4	1	2.71

Supernus Pharmaceuticals has a consensus target price of $62.83, suggesting a potential upside of 32.42%. Given Supernus Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Supernus Pharmaceuticals is more favorable than Vectura Group.

Summary

Supernus Pharmaceuticals beats Vectura Group on 8 of the 13 factors compared between the two stocks.

About Vectura Group

Vectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.